Veritas In Silico Inc. (TYO:130A)

Revenue by Segment

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Drug Discovery Platform Business	91.14M	194.64M	360.36M	178.80M	59.33M
Total	91.14M	194.64M	360.36M	178.80M	59.33M

Revenue by Geography

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Japan	91.14M	194.64M	360.36M	178.80M	59.33M
Total	91.14M	194.64M	360.36M	178.80M	59.33M

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 24, 2026

Data Sources Report a data error